Market capitalization | $3.72b |
Enterprise Value | $3.32b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 9.48 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-781.27m |
Free Cash Flow (TTM) Free Cash Flow | $-485.24m |
Cash position | $437.10m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
13 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
13 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -408 -408 |
28%
28%
|
|
Depreciation and Amortization | 3.37 3.37 |
142%
142%
|
|
Stock Compensation | 29 29 |
85%
85%
|
|
Operating Cash Flow | -332 -332 |
11%
11%
|
|
Investments | 3.05 3.05 |
93%
93%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -335 -335 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Head office | Virgin Islands, British |
CEO | Vladimir Coric |
Employees | 239 |
Founded | 2022 |
Website | www.biohaven.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.